HUTCHMED (China) Limited
NASDAQ:HCMDrug Manufacturers - Specialty & Generic
+$0.16 today
- Market cap
- $2.44B
- Beta
- 0.37
- P/E (TTM)
- 46.2
- EPS (TTM)
- $0.05
Volume 0.04M
Average 0.04M
HCM Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
HUTCHMED (China) LimitedNASDAQ: HCM
Depreciation & Amortization · Q2 FY2025 · quarter ended Jun 2025
Depreciation & amortization dips below year-ago levels
Q2 FY2025 depreciation & amortization of $3.06M fell 2.1% year over year, behind the +14.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +15.5% a year.
Context
- Depreciation & amortization amounted to 2.4% of revenue in FY2025, up 0.5 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -2.1% toward the trailing-twelve-month pace of +14.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 13.34M USD
- Year-over-year change
- +8.1%
- 4-year CAGR
- +16.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.34M | +8.1% |
| FY2024 | 2024-12-31 | 12.34M | +50.4% |
| FY2023 | 2023-12-31 | 8.21M | -5.3% |
| FY2022 | 2022-12-31 | 8.66M | +20.5% |
| FY2021 | 2021-12-31 | 7.19M | — |
Depreciation & Amortization vs competitors
How HCM compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +14.7% is the 5th highest of 9, against a peer median of +13.5%.
- Depreciation & amortization amounts to 2.0% of revenue for HCM, versus a peer median of 3.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €676.85M EUR | +122.9% | +43.9% | 25.6% | |
| LTM Jun 2026 | $98.28M USD | +8.6% | +11.2% | 1.7% | |
AAPGAscentage Pharma Group International | FY2025 | CN¥86.48M CNY | -7.2% | +11.2% | 15.5% |
| LTM Sep 2026 | $50.27M USD | +111.9% | +16.3% | 3.7% | |
| LTM Jun 2026 | $44M USD | — | -41.9% | 1.1% | |
| LTM Jul 2026 | $28.3M USD | -5.0% | +11.7% | 1.2% | |
| LTM Jun 2026 | $15.93M USD | +21.7% | +22.2% | 3.5% | |
| LTM Jun 2025 | $12.21M USD | +14.7% | +15.5% | 2.0% | |
| LTM Jun 2026 | $10M USD | +0.0% | +18.6% | 8.5% | |
| LTM Mar 2026 | $4.6M USD | +18.5% | +29.8% | 2.0% | |
| LTM Jun 2024 | $2.04M USD | — | -11.5% | 31.4% | |
| Peer median (excluding HCM) | — | +13.5% | +14.0% | 3.6% | |
Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (167.04M) | (360.39M) | 100.78M | 37.73M | 458.12M |
| Depreciation & Amortization | 7.19M | 8.66M | 8.21M | 12.34M | 13.34M |
| Deferred Income Tax | (115.14M) | 0 | (102.76M) | 0 | 0 |
| Stock-Based Compensation | 41.99M | 30.59M | 36.6M | 21.61M | 15.29M |
| Change in Working Capital | 32.46M | 58.7M | 71.15M | (62.17M) | (61.02M) |
| Accounts Receivables | (35.63M) | (14.45M) | (21.34M) | (41.57M) | 28.94M |
| Inventory | (16M) | (21.21M) | 4.14M | (772K) | 9.57M |
| Accounts Payables | 9.57M | 29.94M | (32.54M) | 0 | 3.02M |
| Other Working Capital | 74.53M | 64.04M | 120.89M | (19.82M) | (102.55M) |
| Other Non-Cash Items | (3.68M) | (6.17M) | 105.28M | (9.01M) | (490.56M) |
| Operating Cash Flow | (204.22M) | (268.6M) | 219.26M | 497K | (64.83M) |
| Capital Expenditures | (16.76M) | (36.66M) | (32.61M) | (17.93M) | (14.19M) |
| Acquisitions (Net) | 159.12M | 324K | (2.99M) | 0 | 28.07K |
| Purchases of Investments | (1.37B) | (1.2B) | (1.63B) | (1.85B) | (2.75B) |
| Sales of Investments | 921.36M | 1.52B | 1.37B | 1.77B | 2.74B |
| Other Investing Activities | 930K | 16.49M | 29.5M | 1.28M | 0 |
| Investing Cash Flow | (306.32M) | 296.59M | (291.14M) | (96.06M) | (29.49M) |
| Debt Repayment | (579.77K) | (9.17M) | 61.71M | 5.61M | 6.27M |
| Common Stock Issued | 717.32M | 174K | 5.09M | 790K | 1.58M |
| Common Stock Repurchased | (27.31M) | (48.08M) | (9.07M) | (36.06M) | 0 |
| Dividends Paid | (99.74M) | (87.44M) | 0 | 0 | 0 |
| Other Financing Activities | 60.34M | 61.75M | (9.07M) | (1M) | 0 |
| Financing Cash Flow | 650.03M | (82.76M) | 48.66M | (30.67M) | 7.86M |
| Effect of Forex Changes | 2.43M | (9.49M) | (6.47M) | (3.4M) | 3.83M |
| Net Change in Cash | 141.91M | (64.26M) | (29.69M) | (129.63M) | (82.63M) |
| Free Cash Flow | (220.98M) | (305.26M) | 186.65M | (17.44M) | (79.01M) |
HUTCHMED (China) Limited
NASDAQ:HCM
Intrinsic Alpha fair value
Locked
Current Price
$13.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.